San Diego, CA, gathered 150+ biomarker experts at the “Biomarker Conference” on February 18th to 19th.

With growing pressures of increasing success rates for FDA approved biomarkers, there is a need for a first time right, cost-effective and reliable biomarker discovery and development strategy to secure the essential regulatory approvals. The conference gave its visitors the opportunity to learn and hear more about emerging pathways and breakthroughs in biomarker discovery and successful validation in consort with regulatory guidelines and evolving cost-effective technologies that can help increase success rates in novel biomarker discovery and approvals for clinical utility. Key speakers included  Dr Claudio Carini, Global Head Clinical Immunology and Biomarkers at Pfizer, Dr Suso Platero, Sr. Director Translational Research Oncology at Janssen research & Development and Dr. Abraham Tzou, Medical Officer, Center for Devices and Radiological Health at the FDA/CDRH.